ASCO guidance recommends Iressa
Executive Summary
American Society of Clinical Oncology recommends use of AstraZeneca's Iressa for treatment of non-small cell lung cancer in updated guidance published in 1Journal of Clinical Oncology. FDA approved Iressa (gefinitib) May 5 (2"The Pink Sheet" May 12, 2003, p. 7)...
You may also be interested in...
Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.